Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
456.60 DKK | +0.10% |
|
+5.49% | -26.85% |
May. 21 | Cigna to offer $200 Wegovy, Zepbound weight-loss benefit | RE |
May. 21 | Cigna to offer $200 Wegovy, Zepbound weight-loss benefit | RE |
Main competitors
Revenues (Y-1) | Net margin (Y-1) | EBIT margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
---|---|---|---|---|---|---|---|
40.31B | 34.78% | 44.19% | 80.78% | 25.88% | 0.52x | ||
45.04B | 23.51% | 31.78% | 84.84% | 14.84% | 1.88x | ||
88.82B | 15.84% | 29.8% | 34.23% | 13.95% | 0.36x | ||
56.33B | 7.59% | 41.43% | 263.08% | 13.34% | 2.56x | ||
66.76B | 13.68% | 34.42% | 43.45% | 15.69% | 0.74x | ||
50.32B | 23.73% | 38.74% | 34.74% | 15.58% | 0.85x | ||
54.07B | 13.01% | 31.31% | 32.11% | 12.51% | 1.47x | ||
64.17B | 26.68% | 36.46% | 46.35% | 17.38% | 0.86x | ||
33.42B | 12.24% | 44.96% | 177.29% | 11.36% | 2.33x | ||
28.75B | 1.67% | 29.63% | 27.6% | 9.57% | 1.48x | ||
63.63B | 12.62% | 34.24% | 19.99% | 8.05% | 1.52x | ||
42.53B | 13.98% | 27.61% | 11.75% | 4.43% | 0.68x | ||
11.02B | -4.86% | 6.31% | 0.65% | 0.49% | -6.77x | ||
48.3B | -18.53% | 10.77% | 10.23% | -9.53% | 6.49x | ||
7.45B | 33.09% | 46.3% | 22% | 18.71% | -1.74x | ||
39.28B | 8.21% | 29.16% | 48.09% | 10.97% | 1.22x | ||
3.83B | 22.64% | 26.77% | 14.73% | 13.49% | -2.98x | ||
14.06B | 12.84% | 22.26% | 8.8% | 4.22% | 2.82x | ||
10.59B | 12.53% | 13.21% | 12.8% | 7.95% | -2.01x | ||
Average | 40.46B | 13.96% | 30.49% | 51.24% | 10.99% | 0.65x | |
Weighted average by Cap. | 49.61B | 16.67% | 33.2% | 71% | 13.34% | 1.04x |
- Stock Market
- Equities
- NOVO B Stock
- Sector Novo Nordisk A/S
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions